Información del artículo
El Texto completo está disponible en PDF
Bibliografía General
[1.]
R. Klein.
Hyperglicemia and microvascular and macrovascular disease in diabetes.
Diabetes Care, 18 (1995), pp. 258-268
[2.]
The Diabetes Control and Complications Trial Research Group.
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus.
N Engl J Med, 329 (1993), pp. 977-986
[3.]
Y. Ohkubo, H. Kishikawa, E. Araki, T. Miyata, S. Isami, S. Motoyoshi, et al.
Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6 years study.
Diabetes Res Clin Frac, 28 (1995), pp. 103-117
[4.]
United Kingdom Prospective Diabetes Study Group.
Intensive blood-glucose control with sulfonilureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).
Lancet, 352 (1998), pp. 837-852
[5.]
United Kingdom Prospective Diabetes Study Group.
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).
Lancet, 352 (1998), pp. 854-864
[6.]
S. Vijan, T.P. Hofer, R.A. Hayward.
Estimated benefits of glycemic control in microvascular complications in type 2 diabetes.
Ann Intern Med, 127 (1997), pp. 195-788
[7.]
UK Prospective Diabetes Study Group.
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38).
BMJ, 317 (1998), pp. 703-713
[8.]
American Diabetes Association.
Standards of medical care for patients with diabetes mellitus. Clinical practice recommendations.
Diabetes Care, 23 (2000), pp. 32-42
[9.]
Canadian Diabetes Association.
1998 clinical guidelines for the management of diabetes in Canada.
CMAJ, 159 (1998), pp. 1-29
[10.]
European Diabetes Policy Group 1998-1999.
A desktop guide to type 2 diabetes mellitus.
Diabetic Med, 16 (1999), pp. 716-730
[11.]
Grupo de Estudio de la Dabetes en Atención Primaria de Salud (GEDAPS).
Guía para el tratamiento de la diabetes tipo 2 en la atención primaria (3.a ed.).
[12.]
H.E. Lebovitz.
Therapy for diabetes mellitus and related disorders (3.a ed.).
[13.]
R.A. De Fronzo.
Pharmacologic therapy for type 2 Diabetes Mellitus.
Ann Intern Med, 131 (1999), pp. 281-303
[14.]
S. Haffner, S. Lehto, T. Ronnemaa, K. Pyorala, M. Laakson.
Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.
N Engl J Med, 339 (1998), pp. 229-234
[15.]
H.E. Lebovitz.
Insulin secretagogues: old and new.
Diabetes Rev, 7 (1999), pp. 139-153
[16.]
R. Turner, C. Cull, R. Holman.
UK Prospective Diabetes Study 17: a nine-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non insulin-dependent diabetes mellitus.
Ann Intern Med, 124 (1996), pp. 136-145
[17.]
J. Rosenstock, E. Samols, D.B. Muchmore, J. Schneider.
The Glymepiride Study Group. Glymepiride, a new once-daily suifonylurea: a double-blind placebo-controlled study of NIDDM patients.
Diabetes Care, 19 (1996), pp. 1194-1200
[18.]
K.E. Draeger, K. Wernicke-Panten, H.J. Lomp, E. Schuler, R. Rosskamp.
Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glymepiride (Amaryl): a double-blind comparison with glibenclamide.
Horm Metab Res, 28 (1996), pp. 419-425
[19.]
R.B. Goldberg, S.M. Holvey.
Schnelder. A dose-response study of glymepiride in patients with NIDDM who have previously received sulfonylurea agents.
Diabetes Care, 19 (1996), pp. 849-856
[20.]
G.E. Sonnenberg, D.C. Garg, D.J. Weidler, R.M. Dixon, L.A. Jaber, A.J. Bowen, et al.
Short-term comparison of onceversus twice-daily administration of glymepiride in patients with non insulin-dependent diabetes mellitus.
Ann Pharmacother, 31 (1997), pp. 671-676
[21.]
K. Cusi, R.A. De fronzo.
Metformin: a review of its metabolic effects.
Diabetes Rev, 6 (1998), pp. 89-131
[22.]
K. Johansen.
Efficacy of metformin in the treatment of NIDDM. Metaanalysis.
Diabetes Care, 22 (1999), pp. 33-37
[23.]
A.J. Garber, T.G. Duncan, A.M. Goodman, D.J. Mills, J.L. Rohif.
Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, doseresponse trial.
Am J Med, 102 (1997), pp. 491-497
[24.]
R. Defronzo, A. Goodman, et al.
Efficacy of metformin in patients with NIDDM.
N Engl J Med, 333 (1995), pp. 541-549
[25.]
P.W. Stacpoole.
Metformin and lactic acidosis Guilt by association?.
Diabetes Care, 21 (1998), pp. 1587-1588
[26.]
M. Bayraktar, N. Adalar, D.H. Van Thiel.
A comparison of acarbose versus metformin as an adjunt therapy in sulfonylurea-treated NIDDM patients.
Diabetes Care, 19 (1996), pp. 252-259
[27.]
A.J. Scheen.
Clinical efficacy of acarbose in diabetes mellitus: a critical review of controlled trials.
Diabetes Metabolism, 24 (1998), pp. 311-320
[28.]
R. Coniff, J.A. Shapiro, D. Robbins, R. Kleinfield, T. Seaton, P. Beisswenger, et al.
Reduction of glycosilated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dosecomparison study.
Diabetes Care, 18 (1995), pp. 817-824
[29.]
J. Hoffman, M. Spengler.
Efficacy of 24-week monotherapy with acarbose, glibenclamide or placebo in NIDDM patients.
Diabetes Care, 17 (1994), pp. 561-566
[30.]
R.R. Holman, R.C. Turner, C.A. Cull.
on behalf of the UKPDS Study Group. A randomized double-blind trial of Acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44).
Diabetes Care, 22 (1999), pp. 960-964
[31.]
P. Segal, P.U. Felg, G. Scherntbaner, K.P. Ratzmann, J. Rybka, D. Petzinna, et al.
The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone.
Diabetes Care, 20 (1997), pp. 687-691
[32.]
D.R. Owens.
Repaglinide-prandial glucose regulator: a new class of oral antidiabetic drugs.
Diabet Med, 15 (1998), pp. 28-36
[33.]
T. Marbury, W.C. Huang, P. Strange, H. Lebovitz.
Repaglinide versus glyburide a one-year comparison trial.
Diabetes Res Clin Pract, 43 (1999), pp. 155-166
[34.]
Y. Iwamoto, k. Kosaka, T. Kuzuya, Y. Akaa.
Effects of Troglitazone. A new hipoglycernic agent in patients with NIDDM poorly controlled by diet.
Diabetes Care, 19 (1996), pp. 151-155
[35.]
G.L. Plosker, D. Faulds.
Troglitazone: a review of its use in the management of type 2 diabetes mellitus.
Drugs, 57 (1999), pp. 409-438
[36.]
P. Watkins, R. Whitcomb.
Hepatic dysfunction associated with troglitazone.
N Engl J Med, 338 (1998), pp. 916-917
Copyright © 2001. Elsevier España, S.L.. Todos los derechos reservados
